|
Patients with high risk prostate cancers who have hormone therapy in addition to both
internal and external radiation have a better chance of
beating the disease than patients treated with radiation alone, according to a
new study published in the January 1, 2005, issue of the International Journal
of Radiation Oncology*Biology*Physics.
Since the late 1980s, doctors have been increasingly using internal radiation, also called radioactive seed implants or brachytherapy, to treat prostate cancer.
For patients with higher risk prostate cancers – defined as having at least two of the following three: a high Gleason score, a high PSA score and/or an advanced stage – doctors have been adding hormone therapy and external beam radiation therapy to the treatment plan to try to increase survival rates.
In this study, doctors studied nearly 200 men with high risk prostate cancer over eight years to see if adding hormone therapy to external radiation and brachytherapy did indeed increase disease-free survival rates.
Of the participating patients, 107 men were treated with external beam radiation therapy combined with seed implants. Another 69 patients received hormone therapy in addition to the seed implants and external beam radiation.
After eight years, nearly 94 percent of the men who had hormone therapy in addition to the two types of radiation had no evidence of their prostate cancer, compared with 84 percent of the men who only had seed implants and external beam radiation therapy.
"This is an exciting study because it shows that adding hormone treatment and external beam radiation therapy to seed implants does indeed help men with high risk prostate cancer to live longer without the cancer returning," said Dr. Gregory S. Merrick, lead author of the study and a radiation oncologist at Schiffler Cancer Center in Wheeling, W.Va..
Source: Medical Week staff, week of Dec. 29, 2004
|
HOME PAGE
